Skip to main content

Table 2 Results of ATRX and IDH mutation status stratified by histological diagnosis

From: ATRX immunostaining predicts IDH and H3F3A status in gliomas

Tumor WHO Grade ATRX loss/retention (n)a IDH mutated/WT (n)a IDH mutant & ATRX loss/retention (n)a H3F3A mutant & ATRX loss/retention (n)a
Diffuse Astrocytoma   136/120 (53 %) 156/113 (42 %) 116/20 (85 %)  
 - Low grade II 72/49 (59 %) 86/44 (66 %) 62/12 (84 %)  
 - Anaplastic III 64/71 (47 %) 70/69 (50 %) 52/10 (84 %) 4/0 (100 %)
Oligoastrocytoma   23/48 (32 %) 66/6 (92 %) 23/42 (35 %)  
 - Low grade II 8/31 (21 %) 36/3 (92 %) 8/28 (23 %)  
 - Anaplastic III 15/17 (47 %) 30/3 (91 %) 15/14 (52 %)  
Oligodendroglioma   1/79 (1 %) 81/2 (98 %) 1/77 (1 %)  
 - Low grade II 0/33 (0 %) 35/0 (100 %) 0/33 (0 %)  
 - Anaplastic III 1/46 (2 %) 46/2 (96 %) 1/44 (2 %)  
Glioblastoma IV 47/260 (15 %) 38/295 (11 %) 33/9 (79 %) 5/7 (42 %)
 - Primary IV 27/215 (11 %) 19/224 (7 %) 17/3 (89 %) 5/7 (42 %)
 - Secondary IV 16/14 (53 %) 19/11 (63 %) 14/5 (78 %)  
 - With oligodendroglial component IV 3/10 (23 %) 4/8 (33 %) 3/1 (75 %)  
 - With PNET component IV 0/1 (0 %) 0/1 (0 %)   
 - Gliosarcoma IV 0/6 (0 %) 0/6 (0 %)   
Ependymoma   0/93 (0 %) 0/98 (0 %)   
 - Low grade II 0/43 (0 %) 0/41 (0 %)   
 - Anaplastic III 0/23 (0 %) 0/23 (0 %)   
 - Myxopapillary I 0/18 (0 %) 0/24 (0 %)   
 - Subependymoma I 0/9 (0 %) 0/10 (0 %)   
Pilocytic astrocytoma I 0/57 (0 %) 0/57 (0 %)   
 - Pilomyxoid II 0/1 (0 %) 0/1 (0 %)   
 - Anaplastic III 1/1 (50 %) 0/2 (0 %)   
  1. aValues in brackets show the percentage of tumors with ATRX loss within the respective sample cohort. For Ependymoma and pilocytic, pilomyxoid and anaplastic pilocytic astrocytoma ony the results of IDH1 (R132)-IHC were available